Circio Holding Valuation

Is CRNA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CRNA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CRNA (NOK0.92) is trading below our estimate of fair value (NOK48.91)

Significantly Below Fair Value: CRNA is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for CRNA?

Other financial metrics that can be useful for relative valuation.

CRNA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue450.7x
Enterprise Value/EBITDA-1.1x
PEG Ratio0.04x

Price to Earnings Ratio vs Peers

How does CRNA's PE Ratio compare to its peers?

The above table shows the PE ratio for CRNA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average32.8x
AZT ArcticZymes Technologies
48.2x53.2%NOK 704.8m
NSB NeuroScientific Biopharmaceuticals
16.9xn/aAU$5.2m
532041 Hindustan Bio Sciences
44.4xn/a₹116.2m
NAVA Navamedic
21.8x30.2%NOK 427.4m
CRNA Circio Holding
2.5x61.2%NOK 23.3m

Price-To-Earnings vs Peers: CRNA is good value based on its Price-To-Earnings Ratio (2.5x) compared to the peer average (32.6x).


Price to Earnings Ratio vs Industry

How does CRNA's PE Ratio compare vs other companies in the European Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a1.1%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a1.1%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: CRNA is good value based on its Price-To-Earnings Ratio (2.5x) compared to the European Biotechs industry average (24.1x).


Price to Earnings Ratio vs Fair Ratio

What is CRNA's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CRNA PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio2.5x
Fair PE Ratio18.8x

Price-To-Earnings vs Fair Ratio: CRNA is good value based on its Price-To-Earnings Ratio (2.5x) compared to the estimated Fair Price-To-Earnings Ratio (18.8x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CRNA forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentNOK 0.92
NOK 2.00
+117.9%
50.0%NOK 3.00NOK 1.00n/a2
Oct ’25NOK 0.70
NOK 2.00
+184.1%
50.0%NOK 3.00NOK 1.00n/a2
Sep ’25NOK 1.30
NOK 3.00
+130.8%
66.7%NOK 5.00NOK 1.00n/a2
Aug ’25NOK 2.33
NOK 3.00
+28.8%
66.7%NOK 5.00NOK 1.00n/a2
Jul ’25NOK 2.46
NOK 12.00
+387.8%
91.7%NOK 23.00NOK 1.00n/a2
Jun ’25NOK 3.06
NOK 12.00
+292.2%
91.7%NOK 23.00NOK 1.00n/a2
May ’25NOK 2.50
NOK 48.00
+1,820.0%
107.7%NOK 120.00NOK 1.00n/a3
Apr ’25NOK 6.00
NOK 48.00
+700.0%
107.7%NOK 120.00NOK 1.00n/a3
Mar ’25NOK 6.40
NOK 70.50
+1,001.6%
70.2%NOK 120.00NOK 21.00n/a2
Feb ’25NOK 6.78
NOK 70.50
+940.0%
70.2%NOK 120.00NOK 21.00n/a2
Jan ’25NOK 7.20
NOK 57.00
+691.7%
78.4%NOK 120.00NOK 21.00n/a3
Dec ’24NOK 6.75
NOK 57.00
+744.4%
78.4%NOK 120.00NOK 21.00n/a3
Nov ’24NOK 6.23
NOK 57.00
+815.1%
78.4%NOK 120.00NOK 21.00NOK 1.163
Oct ’24NOK 10.80
NOK 75.00
+594.4%
60.0%NOK 120.00NOK 30.00NOK 0.702
Sep ’24NOK 15.30
NOK 75.00
+390.2%
60.0%NOK 120.00NOK 30.00NOK 1.302
Aug ’24NOK 17.40
NOK 75.00
+331.0%
60.0%NOK 120.00NOK 30.00NOK 2.332
Jul ’24NOK 17.10
NOK 75.00
+338.6%
60.0%NOK 120.00NOK 30.00NOK 2.462
Jun ’24NOK 14.07
NOK 99.00
+603.6%
21.2%NOK 120.00NOK 78.00NOK 3.062
May ’24NOK 18.30
NOK 99.00
+441.0%
21.2%NOK 120.00NOK 78.00NOK 2.502
Apr ’24NOK 21.81
NOK 99.00
+353.9%
21.2%NOK 120.00NOK 78.00NOK 6.002
Mar ’24NOK 24.30
NOK 99.00
+307.4%
21.2%NOK 120.00NOK 78.00NOK 6.402
Feb ’24NOK 29.70
NOK 99.00
+233.3%
21.2%NOK 120.00NOK 78.00NOK 6.782
Jan ’24NOK 32.88
NOK 99.00
+201.1%
21.2%NOK 120.00NOK 78.00NOK 7.202
Dec ’23NOK 35.40
NOK 99.00
+179.7%
21.2%NOK 120.00NOK 78.00NOK 6.752
Nov ’23NOK 33.00
NOK 99.00
+200.0%
21.2%NOK 120.00NOK 78.00NOK 6.232

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.


Discover undervalued companies